A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Brazikumab (Primary) ; Brazikumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Allergan; MedImmune
- 28 Nov 2017 Planned End Date changed from 1 Sep 2019 to 2 Feb 2018.
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2017 This study has been Discontinued in Spain as per European Clinical Trials Database record.